Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 3/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 8/20 | 0.36 |
| ▸ | RXRA | P19793 | 7/20 | 0.36 |
| ▸ | PPARG | P37231 | 7/20 | 0.36 |
| ▸ | RXRB | P28702 | 6/20 | 0.36 |
| ▸ | RXRG | P48443 | 5/20 | 0.36 |
| ▸ | PPARD | Q03181 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13060369 | 0.84 | MEN1 (0.37) | KMT2AMEN1SMN1; SMN2GAAAURKA | |
| SCHEMBL14026511 | 0.81 | PAK4 (0.38) | KMT2AMEN1SMN1; SMN2GAAAURKA | |
| SCHEMBL30702750 | 0.81 | PAK4 (0.38) | KMT2AMEN1SMN1; SMN2GAAAURKA | |
| SCHEMBL3324249 | 0.81 | MAPT (0.43) | KMT2AMEN1SMN1; SMN2GAAAURKA | |
| SCHEMBL12102876 | 0.79 | MEN1 (0.52) | KMT2AMEN1SMN1; SMN2GAAAURKA | |
| SCHEMBL2713578 | 0.79 | MEN1 (0.40) | KMT2AMEN1SMN1; SMN2GAAAURKA | |
| SCHEMBL2957184 | 0.79 | MEN1 (0.40) | KMT2AMEN1SMN1; SMN2GAAAURKA | |
| SCHEMBL91111 | 0.79 | GSK3B (0.35) | KMT2AMEN1SMN1; SMN2GAAAURKA | |
| SCHEMBL2118821 | 0.77 | MEN1 (0.38) | KMT2AMEN1SMN1; SMN2GAAAURKA | |
| SCHEMBL3324241 | 0.76 | AURKA (0.44) | KMT2AMEN1SMN1; SMN2GAAAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954277-B1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMA (US) | 2017-01-18 | — | — | EP | disclosed |
| EP-1954277-B1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMA (US) | 2017-01-18 | — | — | EP | disclosed |
| EP-1948193-B1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMA (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8637511-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637511-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637511-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130324725-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-12-05 | — | — | US | disclosed |
| US-8455507-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120142660-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142660-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-07 | — | — | US | disclosed |
| US-20070249031-A1 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249031-A1 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | US | disclosed |
| CN-100340555-C | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMA (US) | 2007-10-03 | — | — | CN | disclosed |
| WO-2007056164-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056221-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
| CN-1549812-A | Pyrazole compounds useful as protein kinase inhibitors | ��̩��˹ҩ��ɷ�����˾ | 2004-11-24 | — | — | CN | disclosed |
| CN-1487933-A | Pyrazole compounds useful as protein kinase inhibitors | ��̩��˹ҩ��ɷ�����˾ | 2004-04-07 | — | — | CN | disclosed |
| CN-1486312-A | Pyrazole compounds useful as protein kinase inhibitors | ��̩��˹ҩ��ɷ�����˾ | 2004-03-31 | — | — | CN | disclosed |
| CN-1486311-A | Pyrazole compounds useful as protein kinase inhibitors | ��̩��˹ҩ��ɷ�����˾ | 2004-03-31 | — | — | CN | disclosed |
| CN-1486310-A | Pyrazole compounds useful as protein kinase inhibitors | ��̩��˹ҩ��ɷ�����˾ | 2004-03-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142660-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | ABL1, PRKDC, MAP3K5 | KMT2A 913/4885MEN1 2799/4885SMN1; SMN2 2138/4885 |
| US-20130324725-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | AURKC, AURKA, AURKB | KMT2A 773/4885MEN1 1554/4885SMN1; SMN2 2078/4885 |
| US-20070249031-A1 | Aminopyrimidines useful as kinase inhibitors | ABL1, PRKDC, MAP3K5 | KMT2A 913/4885MEN1 2799/4885SMN1; SMN2 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.